Harlan CRS and Bertin Pharma Sign Early Drug Development Agreement

Harlan Contract Research Services (CRS) and Bertin Pharma have announced a strategic partnership to offer a comprehensive package for early drug development. Under the agreement, the companies will offer a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, especially in the context of regulatory studies.

Through the alliance, Harlan CRS will strengthen its drug discovery and translational medicine offerings utilising Bertin Pharma’s expertise in immunology and biomarkers.

“The new agreement benefits us both strategically and scientifically,” said Ciriaco Maraschiello, Director of Strategic Initiatives and Director of Drug Discovery and Translational Medicine at Harlan CRS. “Working together, we will provide the pharmaceutical industry with the best team of scientists to increase the likelihood of success for new generation drugs.”

“PharmImmune, our joint offer with the French Alternative Energies and Atomic Energy Commission (CEA), is the perfect example of an innovative tool that we will be able to better utilise through our agreement with Harlan CRS,” said Pascal Clayette, Head of the Immuno-Pharmacology department at Bertin Pharma.

Harlan Contract Research Services, +44 1332 792896, crs.eu@harlan.com, www.harlan.com/crs. 

Bertin Pharma, +33 1 39 30 62 60, info@bertinpharma.com, www.bertinpharma.com.